What Doxy-PEP Can—and Cannot—Promise
Why does doxycycline post-exposure prophylaxis produce different results against syphilis, chlamydia and gonorrhoea when the regimen is broadly the same? The evidence supports a layered answer rather than a single molecular slogan: a timely dose must create a useful opportunity at relevant mucosal sites, meet a pathogen that remains sufficiently susceptible, and be used in a population and care system where benefit can be observed and managed. This series has followed those layers so readers can make a conditional judgment about doxy-PEP—one that recognizes substantial prevention without turning it into universal protection.
Why one dose produces three outcomes
The strongest evidence is not that doxy-PEP affects “bacteria” in the abstract. It is that, among the populations represented in the randomized trials, an event-driven 200 mg dose taken after condomless sex reduced the incidence of three named infections by different amounts and with different certainty.
WHO’s pooled estimates are the clearest summary. Relative risk was 0.20 for syphilis, with high-certainty evidence; 0.15 for chlamydia, also with high certainty; and 0.52 for gonorrhoea, with moderate-certainty evidence. Those figures correspond approximately to 80%, 85% and 48% lower relative risk under the studied conditions. The differences are large enough to shape interpretation: syphilis and chlamydia show a stronger and more consistent preventive signal, while gonorrhoea shows meaningful benefit but a smaller and more setting-dependent one.
The answer begins with the pathogen. “Bacterial STI” is a useful public-health category, but it does not identify one biological target. Treponema pallidum, Chlamydia trachomatis and Neisseria gonorrhoeae have different susceptibility profiles. WHO explicitly links the gonorrhoea effect to the prevalence of circulating tetracycline resistance. A dose can therefore be taken correctly and still have a different expected effect depending on the bacterial population it encounters. The pooled gonorrhoea estimate is an average across settings, not a universal property of every gonococcal exposure.
The answer also includes the clock. Doxy-PEP is not a general instruction to take doxycycline around sex. The studied intervention is one 200 mg dose ideally within 24 hours and no later than 72 hours, with no more than 200 mg in a 24-hour period. WHO says the interval reflects trial protocols and doxycycline’s pharmacological profile, including differences in distribution across mucosal tissues. The evidence establishes that timing and site matter, but it does not provide a complete tissue-by-tissue map or a precise individual prediction.
That is why a common dose can be a common input without producing a common output. Timing establishes an opportunity. Distribution determines whether drug exposure reaches relevant sites in that opportunity. Pathogen susceptibility determines whether the target can respond. The population and service context determine whether the regimen is used as studied, whether infection is detected and whether changing risks can be managed. These are linked conditions, not interchangeable explanations.
The trial record reinforces this conclusion. In IPERGAY, doxy-PEP substantially reduced chlamydia and syphilis but did not show a statistically significant reduction in gonorrhoea. In the U.S. DoxyPEP and French DOXYVAC trials, gonorrhoea reductions were observed, although they remained smaller than the reductions for chlamydia and syphilis. The difference among studies does not mean that one trial must be accepted and another rejected. It shows that the gonorrhoea branch is sensitive to context, including local susceptibility and other differences in population, exposure, adherence, outcome measurement and statistical precision.
The right synthesis is therefore neither “doxy-PEP works equally against all three” nor “doxy-PEP works against two but not the third.” It works as a prevention strategy with pathogen-specific performance. Syphilis and chlamydia provide the most dependable evidence of substantial benefit in the studied populations.